Transforming ADC Development with Novel Linker Architectures and Payload Optimization
In this scientific poster, we showcase four innovative linker-payload strategies engineered to elevate both the therapeutic performance and scalable manufacturability of antibody-drug conjugates (ADCs).
Together, these cutting-edge advancements form a highly versatile next-generation ADC platform, seamlessly integrating precise targeting capabilities, optimized pharmacological profiles, and robust, industrial-scale manufacturing processes to drive progress in clinical oncology. All chemical components featured are readily accessible to ADC researchers, with every presented payload, linker product, and their respective analogues available through custom synthesis services at WuXi XDC.
All these payload and linker products and their analogues are available via custom synthesis at WuXi XDC. Investigators are granted freedom to operate (FTO) during the R&D stage when such materials are supplied by WuXi XDC.